Patient who underwent Allogeneic hematopoietic stem cell transplantation (allo-HSCT) for various haematological malignancies
Conditions
Brief summary
GRFS (Graft-versus-host disease and Relapse-Free Survival) rate at 1 year post-allograft.
Detailed description
Survival at 1 and 2 years (overall and progression-free), Evaluation of hematological criteria, Assessment of GVHD, Incidence of infectious complications, Tolerance and safety of post-allo-HSCT FMT, Evolution of the composition and diversity of the microbiota, Quality of life
Interventions
Sponsors
CHU Gabriel-Montpied
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GRFS (Graft-versus-host disease and Relapse-Free Survival) rate at 1 year post-allograft. | — |
Secondary
| Measure | Time frame |
|---|---|
| Survival at 1 and 2 years (overall and progression-free), Evaluation of hematological criteria, Assessment of GVHD, Incidence of infectious complications, Tolerance and safety of post-allo-HSCT FMT, Evolution of the composition and diversity of the microbiota, Quality of life | — |
Countries
France
Outcome results
None listed